Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Urinary Bladder Neck Obstruction 1Multiple Endocrine Neoplasia Type 1 1Lower Urinary Tract Symptoms 1

Interventions

Everolimus 27pembrolizumab 25Temozolomide 24lutetium Lu 177 dotatate 22Nivolumab 18Magnetic Resonance Spectroscopy 18lenvatinib 17cabozantinib 17Cisplatin 16Sunitinib 15Capecitabine 14Bevacizumab 14Specimen Handling 12Sorafenib 12trametinib 10Ipilimumab 10Etoposide 10pasireotide 9dabrafenib 9Paclitaxel 9Carboplatin 8pazopanib 7lanreotide 7Octreotide 7Fluorodeoxyglucose F18 7anlotinib 6Irinotecan 6Injections 6Doxorubicin 6surufatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × mirabegron × Endocrine × Clear all
NCT00410514 2014-04-04

A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)

Astellas Pharma Inc

Phase 2 Completed
200 enrolled 24 charts
EndocrineGenitourinary

Urinary Bladder Neck Obstruction, Multiple Endocrine Neoplasia Type 1, Lower Urinary Tract Symptoms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡